Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NQO1 | P15559 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14300622 | 0.76 | ALDH1A1 (0.42) | ALDH1A1LMNAMEN1KMT2ACYP1A2 | |
| SCHEMBL765894 | 0.75 | NQO1 (0.35) | ALDH1A1LMNANQO1ALOX15HSD17B10 | |
| SCHEMBL21871901 | 0.73 | NQO1 (0.33) | NQO1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL16373610 | 0.72 | SLC6A4 (0.37) | — | |
| SCHEMBL21782363 | 0.72 | — | — | |
| SCHEMBL2817980 | 0.71 | NQO1 (0.32) | NQO1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL420547 | 0.71 | HSP90AA1 (0.32) | NQO1HSD17B10CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL12731449 | 0.70 | CYP1A2 (0.33) | ALDH1A1NQO1ALOX15CYP1A1CYP1A2 | |
| SCHEMBL14271768 | 0.69 | KDM4E (0.38) | ALDH1A1LMNACYP1A2 | |
| SCHEMBL2737291 | 0.68 | NOTUM (0.32) | NQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101460476-B | Organic compounds | NOVARTIS AG | 2013-12-04 | — | — | CN | disclosed |
| CN-101460476-A | Organic compounds | NOVARTIS AG (CH) | 2009-06-17 | — | — | CN | disclosed |
| US-7183411-B2 | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-27 | — | — | US | disclosed |
| US-20040157865-A1 | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-08-12 | — | — | US | disclosed |
| WO-2004007459-A2 | NAPHTHOL, QUINOLINE AND ISOQUINOLINE-DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157865-A1 | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor | OPRL1, VRK1, OPRK1 | ALDH1A1 1345/4885LMNA 3162/4885NQO1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.